Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 1
1975 2
1976 2
1977 3
1978 6
1979 2
1980 7
1981 9
1982 6
1983 8
1984 8
1985 10
1986 11
1987 8
1988 8
1989 8
1990 5
1991 6
1992 8
1993 6
1994 5
1995 4
1996 5
1997 2
1998 4
1999 1
2000 1
2001 4
2003 2
2004 1
2005 1
2007 1
2008 3
2009 1
2011 3
2012 5
2013 3
2015 1
2016 1
2019 1
2020 1
2021 2
2022 1
2023 1
2024 2
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

176 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Acute Treatments for Episodic Migraine in Adults: A Systematic Review and Meta-analysis.
VanderPluym JH, Halker Singh RB, Urtecho M, Morrow AS, Nayfeh T, Torres Roldan VD, Farah MH, Hasan B, Saadi S, Shah S, Abd-Rabu R, Daraz L, Prokop LJ, Murad MH, Wang Z. VanderPluym JH, et al. JAMA. 2021 Jun 15;325(23):2357-2369. doi: 10.1001/jama.2021.7939. JAMA. 2021. PMID: 34128998 Free PMC article.
Compared with placebo, calcitonin gene-related peptide receptor antagonists (low to high SOE), lasmiditan (5-HT1F receptor agonist; high SOE), dihydroergotamine (moderate to high SOE), ergotamine plus caffeine (moderate SOE), acetaminophen (moderate SOE), antiemetics (low …
Compared with placebo, calcitonin gene-related peptide receptor antagonists (low to high SOE), lasmiditan (5-HT1F receptor agonist; high SOE …
[Flunarizine and dihydroergotamine in the treatment of migraine in children].
Lastra Martínez L, Herranz Fernández J, Arteaga Manjón-Cabez R. Lastra Martínez L, et al. An Esp Pediatr. 1990 Mar;32(3):213-8. An Esp Pediatr. 1990. PMID: 2189328 Review. Spanish.
We administer during 6 months in randomised way dihydroergotamine or flunarizine to 50 children affects of classical or common migraine. A significative improvement was estimated in frequency, intensity and duration of their crisis in 87% with dihydroergotamine and …
We administer during 6 months in randomised way dihydroergotamine or flunarizine to 50 children affects of classical or common migrai …
[Thrombosis prevention with heparin/dihydroergotamine versus heparin/Sintrom in Ender nailing of pertrochanteric fractures].
Schlag G, Gaudernak T, Pelinka H, Redl H, Kuderna H, Poigenfürst J. Schlag G, et al. Unfallchirurgie. 1988 Feb;14(1):12-21. Unfallchirurgie. 1988. PMID: 3284133 Review. German.
The effect of either (randomized) Heparin/Dihydroergotamine (HDHE) or heparin-acenocoumarin (Hep/S) on the incidence of deep-vein thrombosis in the legs was studied in 212 women of more than 60 years of age with hip fractures. ...Therefore we conclude that in traumatology …
The effect of either (randomized) Heparin/Dihydroergotamine (HDHE) or heparin-acenocoumarin (Hep/S) on the incidence of deep-vein thr …
Apparent lack of synergism between heparin and dihydroergotamine in prevention of deep vein thrombosis after elective hip replacement: a randomised double-blind trial reported in conjunction with an overview of previous results.
Gallus AS, Cade JF, Mills KW, Murphy W. Gallus AS, et al. Thromb Haemost. 1992 Sep 7;68(3):238-44. Thromb Haemost. 1992. PMID: 1440484 Clinical Trial.
We report the results of a double-blind, randomised trial of venous thrombosis (VT) prevention in 117 patients having elective hip replacement where low dose heparin alone (5,000 IU sodium heparin given subcutaneously [sc] 8 hourly until the seventh postoperative day) was compare …
We report the results of a double-blind, randomised trial of venous thrombosis (VT) prevention in 117 patients having elective hip replaceme …
Assessment of the consistency of absorption of dihydroergotamine following oral inhalation: pooled results from four clinical studies.
Kellerman DJ, Forst A, Combs DL, Borland S, Kori S. Kellerman DJ, et al. J Aerosol Med Pulm Drug Deliv. 2013 Oct;26(5):297-306. doi: 10.1089/jamp.2012.0999. Epub 2012 Dec 28. J Aerosol Med Pulm Drug Deliv. 2013. PMID: 23273242
BACKGROUND: MAP0004 is an investigational orally inhaled dihydroergotamine (DHE) delivered via a TEMPO( ) metered dose inhaler that was effective in the acute treatment of migraine in a large Phase 3 trial. ...
BACKGROUND: MAP0004 is an investigational orally inhaled dihydroergotamine (DHE) delivered via a TEMPO( ) metered dose inhaler that w …
Dihydroergotamine nasal spray for the acute treatment of migraine.
Ziegler D, Ford R, Kriegler J, Gallagher RM, Peroutka S, Hammerstad J, Saper J, Hoffert M, Vogel B, Holtz N, et al. Ziegler D, et al. Neurology. 1994 Mar;44(3 Pt 1):447-53. doi: 10.1212/wnl.44.3_part_1.447. Neurology. 1994. PMID: 8145914 Clinical Trial.
We conducted a multicenter, double-blind, parallel-group study to compare the efficacy and safety of dihydroergotamine (DHE) nasal spray and placebo over 4 hours in the treatment of migraine. Of the 112 patients enrolled, 100 were included in the "intent-to-treat" efficacy …
We conducted a multicenter, double-blind, parallel-group study to compare the efficacy and safety of dihydroergotamine (DHE) nasal sp …
Dihydroergotamine nasal spray in the treatment of acute migraine.
Treves TA, Kuritzky A, Hering R, Korczyn AD. Treves TA, et al. Headache. 1998 Sep;38(8):614-7. doi: 10.1046/j.1526-4610.1998.3808614.x. Headache. 1998. PMID: 11398305 Clinical Trial.
OBJECTIVE: To evaluate the efficacy and safety of dihydroergotamine (DHE) nasal spray in patients suffering from common or classical migraine. ...RESULTS: No differences were observed in the migraine characteristics or the number of treatments of the patients from the diff …
OBJECTIVE: To evaluate the efficacy and safety of dihydroergotamine (DHE) nasal spray in patients suffering from common or classical …
Bioavailability of intranasal formulations of dihydroergotamine.
van der Kuy PH, Lohman JJ, Hooymans PM, Ter Berg JW, Merkus FW. van der Kuy PH, et al. Eur J Clin Pharmacol. 1999 Nov;55(9):677-80. doi: 10.1007/s002280050692. Eur J Clin Pharmacol. 1999. PMID: 10638398 Clinical Trial.
OBJECTIVE: A comparison of the pharmacokinetic properties of two novel intranasal preparations of dihydroergotamine mesilate (DHEM) with a commercially available intranasal preparation. METHODS: Two intranasal formulations of DHEM in combination with randomly methylated be …
OBJECTIVE: A comparison of the pharmacokinetic properties of two novel intranasal preparations of dihydroergotamine mesilate (DHEM) w …
Treatment of orthostatic hypotension with dihydroergotamine and caffeine.
Hoeldtke RD, Cavanaugh ST, Hughes JD, Polansky M. Hoeldtke RD, et al. Ann Intern Med. 1986 Aug;105(2):168-73. doi: 10.7326/0003-4819-105-2-168. Ann Intern Med. 1986. PMID: 3729199 Clinical Trial.
Dihydroergotamine had a pressor effect in seven of the eight patients during the fasting period (0600 h to 0900 h), but this agent did not counteract the hypotensive effect of eating. Concomitant administration of caffeine (250 mg, 30 minutes before breakfast), however, ma …
Dihydroergotamine had a pressor effect in seven of the eight patients during the fasting period (0600 h to 0900 h), but this agent di …
Dihydroergotamine-heparin prophylaxis of postoperative deep vein thrombosis. A multicenter trial. The Multicenter Trial Committee.
[No authors listed] [No authors listed] JAMA. 1984 Jun 8;251(22):2960-6. doi: 10.1001/jama.1984.03340460038022. JAMA. 1984. PMID: 6371278 Clinical Trial.
Daily radiofibrinogen uptake tests revealed the following DVT rates: Dihydroergotamine mesylate, 0.5 mg, plus heparin sodium, 5,000 IU, 9.4%; dihydroergotamine mesylate, 0.5 mg, plus heparin sodium, 2,500 IU, 16.8%; heparin sodium, 5,000 IU alone, 16.8%; dihydroe …
Daily radiofibrinogen uptake tests revealed the following DVT rates: Dihydroergotamine mesylate, 0.5 mg, plus heparin sodium, 5,000 I …
176 results